Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
Outline of Final Research Achievements |
In ApoE deficient mouse with angiotensin II continuous infusion for 4 weeks as dyslipidemia combined hypertension model, glomerular swelling and sclerosis findings, and albuminuria were found. ARB olmesartan inhibited these renal injuries, but vasodilator hydralazine did not. Statin inhibited the renal injury as well as olmesartan. As the fatty deposition was restrictive, suggesting fatty accumulation is not a main mechanism of the renal injury in these mice. This renal injury is occurred when dyslipidemia and hypertension are combined, suggesting that this renal injury resembles early stage of CKD in human.
|